Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression
The new Centron includes renamed medical education, public relations and market access divisions.
The digital health firm is expanding services to pharma customers, offering to help drugmakers maximize spending on TV and video.
The company said revenue from pharmaceutical and medical device sponsorships and advertisements rose 10.7% but the company put some initiatives on hold.
A deep dive by the think tank Center for Talent Innovation indicates pharma and payers need to widen their definition of health when communicating with women.
The holding company said pharma and health made up 11% of revenues during the first three months of the year.
Wego Health says fixing this problem requires incorporating patient perspectives before and after a product launch.
A more general warning encourages consumers to engage in a personal discussion with their doctor about a drug, and it promotes engagement with longer-format printed or digitally-delivered information.
J&J sues GlaxoSmithKline over Flonase ads, CDC report finds patients with invasive cancer are living for five years or longer have diagnosis, and Bristol-Myers Squibb resubmits its HCV treatment.
Smartphones drove network traffic.
The Trustworthy Accountability of National Advertisers launched its naming-names initiative in November, but the list is empty.
23andMe is back in the DTC game; Sanofi has named its new CEO; drug companies are contemplating a pay-for-performance sales model.
FDA posted a revised draft guidance document on its brief summary and adequate directions for use concerning risk information in DTC print ads to reflect "recent social science research."
The list of objections by the Office of Prescription Drug Promotion, which oversees medical advertising, is a familiar one, and includes concerns such as claims that go beyond the approved indication.
FDA's latest guidance says it is ok to reduce the amount of risk information in print ads, Google amplifies the health information it will serve up with searches and HBO's John Oliver takes on pharmaceutical marketing.
Tina Fascetti is the mid-sized agency's new Chief Creative Officer. CEO Matt Brown (and ICC Lowe alum) tells MM&M the new Guidemark is just getting started.
The FDA is looking into whether abbreviated risk information is a good idea for DTC.
MAHF 2015 Heritage Ad Awards will be given to campaigns for Bentyl, Hytrin and Navane
With the purchase of Olson Communications, the agency aims to serve clients eager for expertise from outside the healthcare industry.
The Austin agency says it beat out FCB, Ogilvy CommonHealth, GSW Worldwide and H4B Chelsea for the work.
The London healthcare brand and research agency will be part of Omnicom's DAS Group.
The American Academy of Pediatricians says an AstraZeneca drug for preemies should be used less often, and the drugmaker is fighting back with an ad campaign that says the new guidelines put too many at risk.
The bad-ad watchdog says the promotional website for the weight-loss medication Suprenza leaves out too much information.
The regulator's latest study will use eye-tracking tools.
The advertising watchdog gave drugmaker Alvogen 15 days to make amends.
The Omnicom-Publicis deal may have been scuttled, but the hunger for deals remains.
The company said it used "inappropriate expressions" in promotions of a blood pressure medication.
The National Association of Boards of Pharmacy says about 97% of surveyed pharmacy sites fail to comply with laws.
The reason: Diovan.
A consumer survey will shape the regulator's position.
A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.